Please login to the form below

Not currently logged in
Email:
Password:

risankizumab

This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.

New data keeps AbbVie’s star pipeline therapies on track

New data keeps AbbVie’s star pipeline therapies on track

Data showed 56% of patients on risankizumab were symptom free after a year’s treatment. ... The analysis showed that 56% of patients on risankizumab were symptom-free after a year’s treatment, compared to 30% of the Stelara group.

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics